If abiraterone becomes the standard care, will there be cost implications?

If abiraterone becomes the standard care, will there be cost implications?

User Photo
obr

3 years
408 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses the impact of cost with the introduction of abiraterone as standard of care for patients with prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Up Next Autoplay
>